- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
January 7th, 2005
Researchers at Lynn Sage Comprehensive Breast Center played a significant role in the U.S. Food and Drug Administration (FDA) approval of ABRAXANE(TM) (paclitaxel protein bound particles for injectable suspension), indicated for the treatment of metastatic breast cancer.
"This approval means that women with metastatic breast cancer no longer need to endure the toxicities associated with solvents and will no longer need steroid premedication when they receive this albumin-bound form of paclitaxel.
|Related News Press|
New Nanodrug Produced in Iran from Milk Thistle May 4th, 2015
Testing Facility for Graphene Enhanced Composite Pipes May 5th, 2015